{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:16:18Z","timestamp":1761894978784,"version":"3.37.0"},"reference-count":109,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2010,1,1]],"date-time":"2010-01-01T00:00:00Z","timestamp":1262304000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gastroenterolog\u00eda y Hepatolog\u00eda"],"published-print":{"date-parts":[[2010,1]]},"DOI":"10.1016\/j.gastrohep.2009.07.003","type":"journal-article","created":{"date-parts":[[2009,11,5]],"date-time":"2009-11-05T12:39:57Z","timestamp":1257424797000},"page":"54-65","source":"Crossref","is-referenced-by-count":15,"title":["Toxicidad hep\u00e1tica inducida por los nuevos f\u00e1rmacos inmunosupresores"],"prefix":"10.1016","volume":"33","author":[{"given":"Elena","family":"Toscano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judit","family":"Cotta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mercedes","family":"Robles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ma Isabel","family":"Lucena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ra\u00fal J.","family":"Andrade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.gastrohep.2009.07.003_bib1","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1157\/13079002","article-title":"Hepatotoxicity due to commonly-used drugs","volume":"28","author":"Garc\u00eda-Cort\u00e9s","year":"2005","journal-title":"Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2009.07.003_bib2","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.gastro.2005.05.006","article-title":"Drug-induced liver injury: An analysis of 461 incidences submitted to the Spanish registry over a 10-year period","volume":"129","author":"Andrade","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastrohep.2009.07.003_bib3","doi-asserted-by":"crossref","first-page":"255","DOI":"10.4321\/S1130-01082008000500001","article-title":"Reexposure in hepatotoxicity: Concept testing or therapeutic accident?","volume":"100","author":"Andrade","year":"2008","journal-title":"Rev Esp Enferm Dig"},{"key":"10.1016\/j.gastrohep.2009.07.003_bib4","doi-asserted-by":"crossref","unstructured":"Andrade RJ, Lucena MI. Drug induced liver disease-mechanisms and diagnosis. En: McDonald JWD, Burroughs AK, Feagan BG (editores). Evidence-based gastroenterology and hepatology. 3 ed. London: Blackwell Ed; 2009.","DOI":"10.1002\/9781444314403.ch47"},{"key":"10.1016\/j.gastrohep.2009.07.003_bib5","series-title":"Drug-induced liver disease","first-page":"662","article-title":"Hepatotoxicy of immunomodulating agents and the transplant situation","author":"Davern","year":"2007"},{"key":"10.1016\/j.gastrohep.2009.07.003_bib6","series-title":"Enfermedad inflamatoria intestinal","first-page":"209","article-title":"Farmacolog\u00eda de la enfermedad inflamatoria intestinal","author":"Hinojosa","year":"2007"},{"key":"10.1016\/j.gastrohep.2009.07.003_bib7","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/0014-4800(65)90007-9","article-title":"Hepatic lipid metabolism in the cortisone-treated rat","volume":"4","author":"Hill","year":"1965","journal-title":"Exp Mol Pathol"},{"key":"10.1016\/j.gastrohep.2009.07.003_bib8","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1042\/bj1030627","article-title":"Effect of glucocorticoid hormones on fatty acid mobilization and reesterification in rat adipose and tissue","volume":"103","author":"Jeanrenaud","year":"1967","journal-title":"Biochem J"},{"key":"10.1016\/j.gastrohep.2009.07.003_bib9","first-page":"346","article-title":"Experimental hepatic injury produced in the rabbit by glucocorticoides","volume":"85","author":"Bhagwat","year":"1968","journal-title":"Arch Pathol"},{"key":"10.1016\/j.gastrohep.2009.07.003_bib10","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1055\/s-2002-30106","article-title":"Drugs and steatohepatitis","volume":"22","author":"Farrell","year":"2002","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.gastrohep.2009.07.003_bib11","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1345\/aph.1H171","article-title":"Methylprednisolone-induced toxic hepatitis","volume":"40","author":"Topal","year":"2006","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.gastrohep.2009.07.003_bib12","first-page":"720","article-title":"Recurrent acute liver toxicity from intravenous methylprednisolone","volume":"100","author":"Rivero Fern\u00e1ndez","year":"2008","journal-title":"Rev Esp Enferm Dig"},{"key":"10.1016\/j.gastrohep.2009.07.003_bib13","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/S0041-1345(98)00361-3","article-title":"Inmunosupresive agents: Recent developments in molecular action and clinical application","volume":"30","author":"Gerber","year":"1998","journal-title":"Transplant Proc"},{"key":"10.1016\/j.gastrohep.2009.07.003_bib14","doi-asserted-by":"crossref","first-page":"849","DOI":"10.3109\/00365529309103124","article-title":"Cyclosporin for inflammatory bowel disease: Mechanisms and possible actions","volume":"28","author":"Brynskov","year":"1993","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2009.07.003_bib15","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1097\/00042737-200012060-00015","article-title":"Audit of cyclosporin use in inflammatory bowel disease: Limited benefits, numerous side-effects","volume":"12","author":"Haslam","year":"2000","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2009.07.003_bib16","first-page":"314","article-title":"Pharmacocinetique et effects h\u00e9patiques de la cyclosporine A","volume":"16","author":"Cadranel","year":"1992","journal-title":"Gastroenterol Clin Biolog"},{"key":"10.1016\/j.gastrohep.2009.07.003_bib17","first-page":"611","article-title":"Histologic changes in liver allograft biopsies associated with elevated whole blood and tissue cyclosporine concentrations","volume":"5","author":"Wisecarver","year":"1992","journal-title":"Mod Pathol"},{"key":"10.1016\/j.gastrohep.2009.07.003_bib18","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1097\/00007890-198112000-00007","article-title":"Cyclosporin A hepatotoxicity in 66 renal allographt recipients","volume":"32","author":"Klintmalm","year":"1981","journal-title":"Transplantation"},{"key":"10.1016\/j.gastrohep.2009.07.003_bib19","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/BF01540169","article-title":"Liver injury from cyclosporine A","volume":"35","author":"Kassianides","year":"1990","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.gastrohep.2009.07.003_bib20","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/j.1600-0676.1995.tb00692.x","article-title":"Hepatotoxicity of intravenous cyclosporin A in patients with acute ulcerative colitis on total parenteral nutrition","volume":"15","author":"Actis","year":"1995","journal-title":"Liver"},{"key":"10.1016\/j.gastrohep.2009.07.003_bib21","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1097\/00007611-199508000-00010","article-title":"Cyclosporine-induced worsening of hepatic dysfunction in a patient with Crohn's disease and enterocutaneous fistula","volume":"88","author":"Moore","year":"1995","journal-title":"South Med J"},{"key":"10.1016\/j.gastrohep.2009.07.003_bib22","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/S0889-8553(21)00237-5","article-title":"Hepatotoxicity of transplant immunosuppresive agents","volume":"24","author":"Kowdley","year":"1995","journal-title":"Gastroenterol Clin North Am"},{"key":"10.1016\/j.gastrohep.2009.07.003_bib23","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1093\/clinchem\/34.9.1767","article-title":"Liver-function studies in heart transplant recipients treated with cyclosporin A","volume":"34","author":"Gulbis","year":"1988","journal-title":"Clin Chem"},{"key":"10.1016\/j.gastrohep.2009.07.003_bib24","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1517\/14740338.1.2.159","article-title":"The rational use of potentially hepatotoxic medications in patients with underlying liver disease","volume":"1","author":"Lewis","year":"2002","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.gastrohep.2009.07.003_bib25","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/0190-9622(90)70358-O","article-title":"The role of cytochromes P-450 in cyclosporine metabolism","volume":"23","author":"Watkins","year":"1990","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.gastrohep.2009.07.003_bib26","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1007\/BF02088068","article-title":"Improvement of cyclosporin A-induced cholestasis by tauroursodeoxycholate in a long-term study in the rat","volume":"39","author":"Queneau","year":"1994","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.gastrohep.2009.07.003_bib27","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/00007890-198701000-00009","article-title":"Hepatobiliary and pancreatic complications of cyclosporine therapy in 466 renal transplant recipients","volume":"43","author":"Lorber","year":"1987","journal-title":"Transplantation"},{"key":"10.1016\/j.gastrohep.2009.07.003_bib28","first-page":"396","article-title":"Asymptomatic gallstones and duration of cyclosporine use in kidney transplant recipients","volume":"53","author":"Alberu","year":"2001","journal-title":"Rev Invest Clin"},{"key":"10.1016\/j.gastrohep.2009.07.003_bib29","first-page":"863","article-title":"Cholelithiasis in pancreas and kidney transplant recipients with diabetes","volume":"114","author":"Lowell","year":"1993","journal-title":"Surgery"},{"key":"10.1016\/j.gastrohep.2009.07.003_bib30","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1272\/jnms.75.187","article-title":"Hepatotoxicity caused by both tacrolimus and cyclosporine after living donor liver transplantation","volume":"75","author":"Taniai","year":"2008","journal-title":"J Nippon Med Sch"},{"key":"10.1016\/j.gastrohep.2009.07.003_bib31","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1111\/j.1432-2277.2005.00210.x","article-title":"Sirolimus-associated hepatotoxicity in the kidney graft recipient","volume":"18","author":"Niemczyk","year":"2005","journal-title":"Transp Int"},{"key":"10.1016\/j.gastrohep.2009.07.003_bib32","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1111\/j.1572-0241.2000.03287.x","article-title":"Hepatic effects of long term methotrexate use in the tratment of inflamatory bowel disease","volume":"95","author":"Te","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2009.07.003_bib33","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1186\/ar419","article-title":"Molecular action of methotrexate in inflammatory diseases","volume":"4","author":"Chan","year":"2002","journal-title":"Arthritis Res"},{"key":"10.1016\/j.gastrohep.2009.07.003_bib34","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1124\/pr.57.2.3","article-title":"Low-dose methotrexate: A main stay in the treatment of rheumatoid arthritis","volume":"57","author":"Cronstein","year":"2005","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.gastrohep.2009.07.003_bib35","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1002\/hep.20708","article-title":"Homocysteine, the bad thiol","volume":"41","author":"Mato","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2009.07.003_bib36","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1016\/S0016-5085(03)00276-2","article-title":"Betaine decreases hyperhomocysteinemia, endoplasmic reticulum stress, and liver injury in alcohol-fed mice","volume":"124","author":"Ji","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastrohep.2009.07.003_bib37","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1001\/archderm.1973.01620220007001","article-title":"Methotrexate therapy for psoriasis: Guideline revisions","volume":"108","author":"Roenigk","year":"1973","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.gastrohep.2009.07.003_bib38","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1136\/bmj.1.5750.625","article-title":"Liver damage due methotrexate in patients with psoriasis","volume":"1","author":"Dahl","year":"1971","journal-title":"Br Med J"},{"key":"10.1016\/j.gastrohep.2009.07.003_bib39","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1111\/j.1365-2133.1995.tb02754.x","article-title":"Sequential liver biopsies during long-term methotrexate treatment for psoriasis: A reapprisal","volume":"133","author":"Boffa","year":"1995","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.gastrohep.2009.07.003_bib40","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/j.1365-2036.2005.02343.x","article-title":"Review article: Monitoring of immunomodulators in inflammatory bowel disease","volume":"21","author":"Aberra","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gastrohep.2009.07.003_bib41","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/1523-1747.ep12500067","article-title":"Complications in methotrexate treatment of psoriasis with particular reference to liver fibrosis","volume":"79","author":"Ashton","year":"1982","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.gastrohep.2009.07.003_bib42","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1046\/j.1365-2036.1996.70244000.x","article-title":"Review article: Methotrexate in gastroenterology. Dangerous villain or simply misunderstood?","volume":"10","author":"Tang","year":"1996","journal-title":"Aliment Pharmacol Ther"},{"year":"2003","series-title":"Drug-induced liver disease","author":"Kaplowitz","key":"10.1016\/j.gastrohep.2009.07.003_bib43"},{"key":"10.1016\/j.gastrohep.2009.07.003_bib44","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/j.jhep.2007.01.024","article-title":"Psoriasis patients with diabetes type 2 are at high risk of developing liver fibrosis during methotrexate treatment","volume":"46","author":"Rosenberg","year":"2007","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastrohep.2009.07.003_bib45","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1126\/science.1128294","article-title":"Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse modle of type 2 diabetes","volume":"313","author":"Oscan","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.gastrohep.2009.07.003_bib46","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jhep.2006.06.004","article-title":"ER stress: Can liver cope?","volume":"45","author":"Ji","year":"2006","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastrohep.2009.07.003_bib47","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.jhep.2007.03.017","article-title":"Dangerous liaisons: Drug, host and the environment","volume":"46","author":"Aithal","year":"2007","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastrohep.2009.07.003_bib48","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1046\/j.1365-2036.2004.01819.x","article-title":"Monitoring methotrexate-induced hepatic fibrosis in patients with psoriasis: Are serial liver biopsies justified?","volume":"19","author":"Aithal","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gastrohep.2009.07.003_bib49","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1136\/gut.50.4.485","article-title":"The efficacy of azathioprine for the treatment of inflammatory bowel disease: A 30 year review","volume":"50","author":"Fraser","year":"2002","journal-title":"Gut"},{"key":"10.1016\/j.gastrohep.2009.07.003_bib50","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1111\/j.1365-2036.2005.02636.x","article-title":"Incidence, risk factors and clinical course of thiopurine-induced liver injury in patients with inflamatory bowel disease","volume":"22","author":"Bastida","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gastrohep.2009.07.003_bib51","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1080\/00855920310002726","article-title":"Safety os thiopurines in the treatment of inflammatory bowel disease","volume":"239","author":"De Jong","year":"2003","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2009.07.003_bib52","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1136\/gut.2006.114363","article-title":"Nodular regenerative hyperplasia in patients with inflammatory bowel disease treated with azathioprine","volume":"56","author":"Vernier-Massouille","year":"2007","journal-title":"Gut"},{"key":"10.1016\/j.gastrohep.2009.07.003_bib53","first-page":"256","article-title":"Role of endothelial cell injury in the spectrum of azathioprine-induced liver disease after renal transplant: Light microscopy and ultrastuctural observations","volume":"83","author":"Haboubi","year":"1988","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2009.07.003_bib54","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.jhep.2003.11.024","article-title":"Toxicity of low dose azathioprine and 6-mercaptopurine in rat hepatocytes. Roles of xanthine oxidase and mitochondrial injury","volume":"40","author":"Tapner","year":"2004","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastrohep.2009.07.003_bib55","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1111\/j.1572-0241.2007.01187.x","article-title":"Thiopurine-induced liver injury in patients with inflammatory bowel disease: A systematic review","volume":"102","author":"Gisbert","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2009.07.003_bib56","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1097\/00004836-200303000-00010","article-title":"Hepatotoxicity associated with 6-thioguanine therapy for Crohn's disease","volume":"36","author":"Rulyak","year":"2003","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.gastrohep.2009.07.003_bib57","first-page":"833","article-title":"Oral 6-thioguanine causes late onset splenomegaly and portal hypertension in a subset of children with acute lymphoblastic leukaemia","volume":"122","author":"Stork","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastrohep.2009.07.003_bib58","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S0016-5085(03)00938-7","article-title":"6-thioguanine can cause serious liver injury in inflammatory bowel disease patients","volume":"125","author":"Dubinsky","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastrohep.2009.07.003_bib59","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/j.1399-0012.1987.tb00696.x","article-title":"Cholestasis after azathioprine administration in renal transplant recipients","volume":"1","author":"Loiseau","year":"1987","journal-title":"Clin Transplant"},{"key":"10.1016\/j.gastrohep.2009.07.003_bib60","series-title":"Drug induced liver disease","first-page":"633","article-title":"Immunomodulating agents and the transplant situation","author":"Hebert","year":"2003"},{"key":"10.1016\/j.gastrohep.2009.07.003_bib61","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1002\/hep.510230326","article-title":"Toxicity of azathioprine and monocrotaline in murine sinusoidal endothelial cells and hepatocytes: The role of glutathione and relevance to hepatic venooclusive disease","volume":"23","author":"DeLeve","year":"1996","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2009.07.003_bib62","first-page":"108","article-title":"Comparative toxicity of azathioprine to rat hepatocytes and sinusoidal endothelial cells in culture","volume":"vol 7","author":"Lee","year":"1999"},{"key":"10.1016\/j.gastrohep.2009.07.003_bib63","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/S0168-8278(01)00196-9","article-title":"Mechanisms of azathioprine-induced injury to hepatocytes: Roles of glutathione depletion and mitochondrial injury","volume":"35","author":"Lee","year":"2001","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastrohep.2009.07.003_bib64","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1155\/1998\/294752","article-title":"Cholestatic hepatocellular injury with azathioprine: A case report and review of the mechanisms of hepatotoxicity","volume":"12","author":"Romagnuolo","year":"1998","journal-title":"Can J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2009.07.003_bib65","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1080\/00365520310005082","article-title":"Pharmacological monitoring of azathioprine therapy","volume":"38","author":"Reuther","year":"2003","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2009.07.003_bib66","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1097\/00008571-200208000-00003","article-title":"Azathioprine therapy and adverse drug reactions in patients with inflammatory bowel disease: Impact of thiopurine S-methyltransferase polymorphism","volume":"12","author":"Schwab","year":"2002","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.gastrohep.2009.07.003_bib67","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S1532-0456(03)00022-X","article-title":"A comparasion of hepatoprotective activities of aminoguanidine and N-acetylcysteine in rat against the toxic damage induced by azathioprine","volume":"134","author":"Raza","year":"2003","journal-title":"Comp Biochem Physiol C Toxicol Pharmacol"},{"key":"10.1016\/j.gastrohep.2009.07.003_bib68","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S0149-2918(04)90048-3","article-title":"Leflunomide in the treatment of rheumatoid arthritis","volume":"26","author":"Li","year":"2004","journal-title":"Clin Ther"},{"key":"10.1016\/j.gastrohep.2009.07.003_bib69","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1159\/000091251","article-title":"Leflunomide improves psoriasis in patients with psoriatic arthritis: An in-depth analysis of data from the TOPAS study","volume":"212","author":"Nash","year":"2006","journal-title":"Dermatology"},{"key":"10.1016\/j.gastrohep.2009.07.003_bib70","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1002\/1529-0131(200109)44:9<1984::AID-ART346>3.0.CO;2-B","article-title":"Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group","volume":"44","author":"Cohen","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.gastrohep.2009.07.003_bib71","unstructured":"EMEA pulic statement on leflunomide (Arava). Severe and serious hepatic reactions [citado 30 Abr 2009]. Disponible en: URL: www.emea.europa.eu\/humandocs\/PDFs\/EPAR\/Arava\/561101en.pdf."},{"key":"10.1016\/j.gastrohep.2009.07.003_bib72","doi-asserted-by":"crossref","first-page":"318","DOI":"10.4103\/0019-5359.26608","article-title":"Efficacy and safety of leflunomide alone and in combination with methotrexate in the treatment of refractory rheumatoid arthritis","volume":"60","author":"Antony","year":"2006","journal-title":"Indian J Med Sci"},{"key":"10.1016\/j.gastrohep.2009.07.003_bib73","doi-asserted-by":"crossref","unstructured":"Curtis JR, Beukelman T, Onofrei A, Cassell S, Greenberg J, Kavanaugh A, et al. Elevated liver enzyme tests among rheumatoid arthritis and psoriatic arthritis patients treated with methotrexate and\/or leflunomide. Ann Rheum Dis. 2009;15. Epub ahead of print.","DOI":"10.1136\/ard.2008.101378"},{"key":"10.1016\/j.gastrohep.2009.07.003_bib74","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1053\/gast.2002.33426","article-title":"Biologic therapy of inflammatory bowel disease","volume":"122","author":"Sandborn","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastrohep.2009.07.003_bib75","doi-asserted-by":"crossref","first-page":"4620","DOI":"10.4049\/jimmunol.168.9.4620","article-title":"TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection","volume":"168","author":"Roach","year":"2002","journal-title":"J Immunol"},{"key":"10.1016\/j.gastrohep.2009.07.003_bib76","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1002\/art.20967","article-title":"Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: Results from the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT)","volume":"52","author":"Antoni","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.gastrohep.2009.07.003_bib77","first-page":"25","article-title":"Niacin-like reaction to infliximab infusion in systemic juvenile rheumatoid arthritis","volume":"31","author":"Becker","year":"2004","journal-title":"J Rheumatol"},{"key":"10.1016\/j.gastrohep.2009.07.003_bib78","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","article-title":"Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: Systematic review and meta-analysis of rare Harmful effects in randomized controlled trials","volume":"295","author":"Bongartz","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.gastrohep.2009.07.003_bib79","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/S1699-258X(07)73593-3","article-title":"Registro Espa\u00f1ol de Acontecimientos Adversos de Terapias Biol\u00f3gicas en Enfermedades Reum\u00e1ticas (BIOBADASER): informe de la situaci\u00f3n, 26 de enero de 2006","volume":"3","author":"Descalzo","year":"2007","journal-title":"Reumatol Clin"},{"key":"10.1016\/j.gastrohep.2009.07.003_bib80","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(00)01034-5","article-title":"Therapeutic monoclonal antibodies","volume":"355","author":"Breedveld","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.gastrohep.2009.07.003_bib81","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.jaad.2006.12.003","article-title":"Adalimumab for severe psoriasis and psoriatic arthritis: An open-label study in 30 patients previously treated with others biologic","volume":"57","author":"Papoutsaki","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.gastrohep.2009.07.003_bib82","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1002\/art.1780351008","article-title":"Increased levels of soluble tumor necrosis factor receptors in the sera and synovial fluid of patients with rheumatic disease","volume":"35","author":"Cope","year":"1992","journal-title":"Arthitis Reum"},{"key":"10.1016\/j.gastrohep.2009.07.003_bib83","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(00)02530-7","article-title":"Etanercept in the treatment of psoriatic arthritis and psoriasis: A randomized trial","volume":"356","author":"Mease","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.gastrohep.2009.07.003_bib84","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1097\/00005176-200502000-00026","article-title":"Hepatoesplenic T-cell lymphoma in an adolescent patient after immunomodulator and biologic therapy for Crohn disease","volume":"40","author":"Thayu","year":"2005","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.gastrohep.2009.07.003_bib85","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.gcb.2008.04.010","article-title":"H\u00e9patotoxicit\u00e9 des medicaments inmunosupresseurs. Conduite diagnostique","volume":"32","author":"Larrey","year":"2008","journal-title":"Gastroenterol Clin Biol"},{"key":"10.1016\/j.gastrohep.2009.07.003_bib86","unstructured":"Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group."},{"key":"10.1016\/j.gastrohep.2009.07.003_bib87","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","article-title":"Maintenance infliximab for Crohn's disease: The ACCENT I randomised trial","volume":"359","author":"Hanauer","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.gastrohep.2009.07.003_bib88","unstructured":"FDA Briefing document. Arthritis Advisory Committee [15 Jun 2009]. Disponible en: URL:http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/03\/transcripts\/3930T1.htm"},{"key":"10.1016\/j.gastrohep.2009.07.003_bib89","doi-asserted-by":"crossref","first-page":"524","DOI":"10.5694\/j.1326-5377.2007.tb01396.x","article-title":"Autoimmune hepatitis following infliximab therapy for ankylosing spondylitis","volume":"187","author":"Ozorio","year":"2007","journal-title":"Med J Aust"},{"key":"10.1016\/j.gastrohep.2009.07.003_bib90","first-page":"73","article-title":"Hepatitis autoinmune inducida por medicamentos","volume":"101","author":"Castiella Eguzkiza","year":"2009","journal-title":"Rev Esp Enferm Dig"},{"key":"10.1016\/j.gastrohep.2009.07.003_bib91","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.3899\/jrheum.080521","article-title":"Hepatotoxicity associated with etanercept in psoriatic artritis","volume":"35","author":"Leak","year":"2008","journal-title":"J Rheumatol"},{"key":"10.1016\/j.gastrohep.2009.07.003_bib92","first-page":"349","article-title":"Granulomatous hepatitis associated with etanercept therapy","volume":"35","author":"Farah","year":"2008","journal-title":"J Rheumatol"},{"key":"10.1016\/j.gastrohep.2009.07.003_bib93","unstructured":"Davern TJ, Moawad D, Ferrell L. Liver injury from TNF antagonist-a class effect? AASLD Single Topic Conference on Drug Induced Liver Injury. Conferencia de la Asociaci\u00f3n Americana para el estudio de la Enfermedad Hep\u00e1tica (AASLD); 2005"},{"key":"10.1016\/j.gastrohep.2009.07.003_bib94","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1177\/039463200902200234","article-title":"Successful treatment with etanercept of a patient with psoriatic arthritis after adalimumab-related hepatotoxicity","volume":"22","author":"Massarotti","year":"2009","journal-title":"Int J Immunopathol Pharmacol"},{"key":"10.1016\/j.gastrohep.2009.07.003_bib95","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1365-2036.2008.03878.x","article-title":"Early clinical experience with adalimumab in treatment of inflammatory bowel disease with infliximab-treated and na\u00efve patients","volume":"29","author":"Swaminath","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gastrohep.2009.07.003_bib96","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1007\/s10067-006-0253-y","article-title":"Successful treatment with etanercept in a patient with hepatotoxicity closely related to infliximab","volume":"26","author":"Garc\u00eda-Aparicio","year":"2007","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.gastrohep.2009.07.003_bib97","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.jbspin.2007.12.009","article-title":"Infliximab-induced hepatitis: Absence of cross-toxicity with etanercept","volume":"75","author":"Thiefin","year":"2008","journal-title":"Joint Bone Espine"},{"key":"10.1016\/j.gastrohep.2009.07.003_bib98","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.jbspin.2008.07.005","article-title":"Liver toxicity of TNF-\u03b1 antagonists","volume":"75","author":"Larrey","year":"2008","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.gastrohep.2009.07.003_bib99","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/j.1365-2133.2008.08673.x","article-title":"Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: A meta-analysis of randomized controlled trials","volume":"159","author":"Brimhall","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.gastrohep.2009.07.003_bib100","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1046\/j.1365-2249.1998.00469.x","article-title":"Induction of tumor necrosis factor (TNF) receptor type p55 and p75 in patients with chronic hepatitis C virus (HCV) infection","volume":"111","author":"Kallinowski","year":"1998","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.gastrohep.2009.07.003_bib101","first-page":"1372","article-title":"Concentrations of cytokines, soluble interleukin-2 receptor, and soluble CD30 in sera of patients with hepatitis B virus infection during acute and convalescent phases","volume":"9","author":"Monsalve-DeCastillo","year":"2002","journal-title":"Clin Diagn Lab Immunol"},{"key":"10.1016\/j.gastrohep.2009.07.003_bib102","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0168-8278(99)80060-9","article-title":"Soluble tumor necrosis factor receptors in chronic hepatitis C: A correlation with histological fibrosis and activity","volume":"30","author":"Zylberberg","year":"1999","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastrohep.2009.07.003_bib103","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1136\/ard.2004.028209","article-title":"Safety of antitumour necrosis factor (anti-TNF) therapy in patients with chronic viral infections: Hepatitis C, hepatitis B and HIV infection","volume":"63","author":"Calabrese","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.gastrohep.2009.07.003_bib104","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.semarthrit.2007.10.011","article-title":"Use of tumor necrosis factor-alpha inhibitors in patients with chronic hepatitis B infection","volume":"38","author":"Carroll","year":"2008","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.gastrohep.2009.07.003_bib105","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1007\/s10067-009-1149-4","article-title":"Use of tumor necrosis factor-\u03b1 (TNF-\u03b1) antagonists infliximab, etanercept, and adalimumab in patients with concurrent rheumatoid arthritis and hepatitis B or hepatitis C: A retrospective record review of 11 patients","volume":"28","author":"Li","year":"2009","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.gastrohep.2009.07.003_bib106","first-page":"1624","article-title":"Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for an adult onset Still's disease","volume":"30","author":"Michel","year":"2003","journal-title":"J Rheumatol"},{"key":"10.1016\/j.gastrohep.2009.07.003_bib107","doi-asserted-by":"crossref","first-page":"974","DOI":"10.3748\/wjg.v12.i6.974","article-title":"Subfulminant hepatitis B after infliximab in Crohn's disease: Need for HBV-screening?","volume":"12","author":"Millonig","year":"2006","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2009.07.003_bib108","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.semarthrit.2007.10.011","article-title":"Use of tumor necrosis factor-alpha inhibitors in patients with chronic hepatitis B infection","volume":"38","author":"Carroll","year":"2008","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.gastrohep.2009.07.003_bib109","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1056\/NEJMct055183","article-title":"Tumor necrosis factor inhibitors for rheumatoid arthritis","volume":"355","author":"Scott","year":"2006","journal-title":"N Engl J Med"}],"container-title":["Gastroenterolog\u00eda y Hepatolog\u00eda"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0210570509004798?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0210570509004798?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T02:25:37Z","timestamp":1739413537000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0210570509004798"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,1]]},"references-count":109,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,1]]}},"alternative-id":["S0210570509004798"],"URL":"https:\/\/doi.org\/10.1016\/j.gastrohep.2009.07.003","relation":{},"ISSN":["0210-5705"],"issn-type":[{"type":"print","value":"0210-5705"}],"subject":[],"published":{"date-parts":[[2010,1]]}}}